Fotemustine plus dacarbazine for malignant melanoma
Identifieur interne : 000845 ( Istex/Corpus ); précédent : 000844; suivant : 000846Fotemustine plus dacarbazine for malignant melanoma
Auteurs : Marie-F Avril ; Jean Bonneterre ; Didier Cupissol ; Jean-J Grob ; Bernard Kalis ; Pierre Fumoleau ; Pierre Kerbrat ; Lucien Israel ; Pierre Fargeot ; Daniel Lambert ; Michelle Delaunay ; Brigitte Dreno ; Catherine Vilmer ; Jean-P Bizzari ; Véronique CourSource :
- European Journal of Cancer [ 0959-8049 ] ; 1992.
English descriptors
- Teeft :
- Alkaline phosphatases, Biometric parameters, Cancer chemother, Centre, Cerebral lesions, Cerebral metastases, Chemotherapy, Clinical trials, Combination chemotherapy, Complete response, Complete responses, Dacarbazine, Disease progression, Dominant metastatic site, Early death, Eurj cancer, Evaluable, Evaluable patients, Final evaluation, Fotemustine, Grade leukopenia, Haematological, Haematological toxicity, High performance, Hopital, Induction cycle, Lesion, Limb perfusion, Maintenance cycle, Malignant, Malignant melanoma, Median, Median days, Median duration, Median durations, Median nadir, Median survival time, Melanoma, Melphalan, Metastasis, Metastatic, Metastatic melanoma, Monotherapy, Natural history, Objective responses, Overall response rate, Partial response, Partial responses, Present series, Prognostic factors, Regimen, Response range, Response rate, Response rates, Toxicity, Visceral lesions, Visceral metastases.
Abstract
Abstract: 119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.
Url:
DOI: 10.1016/0959-8049(92)90008-P
Links to Exploration step
ISTEX:5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Fotemustine plus dacarbazine for malignant melanoma</title><author><name sortKey="Avril, Marie F" sort="Avril, Marie F" uniqKey="Avril M" first="Marie-F" last="Avril">Marie-F Avril</name><affiliation><mods:affiliation>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Bonneterre, Jean" sort="Bonneterre, Jean" uniqKey="Bonneterre J" first="Jean" last="Bonneterre">Jean Bonneterre</name><affiliation><mods:affiliation>Centre Oscar Lambret, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Cupissol, Didier" sort="Cupissol, Didier" uniqKey="Cupissol D" first="Didier" last="Cupissol">Didier Cupissol</name><affiliation><mods:affiliation>Centre Val d'Aurelle, Montpellier, France</mods:affiliation></affiliation></author><author><name sortKey="Grob, Jean J" sort="Grob, Jean J" uniqKey="Grob J" first="Jean-J" last="Grob">Jean-J Grob</name><affiliation><mods:affiliation>Hôpital Sainte-Marguerite, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Kalis, Bernard" sort="Kalis, Bernard" uniqKey="Kalis B" first="Bernard" last="Kalis">Bernard Kalis</name><affiliation><mods:affiliation>Hôpital Sébastopol, Reims, France</mods:affiliation></affiliation></author><author><name sortKey="Fumoleau, Pierre" sort="Fumoleau, Pierre" uniqKey="Fumoleau P" first="Pierre" last="Fumoleau">Pierre Fumoleau</name><affiliation><mods:affiliation>Centre René Gauducheau, Nantes, France</mods:affiliation></affiliation></author><author><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name><affiliation><mods:affiliation>Centre Eugène Marquis, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Israel, Lucien" sort="Israel, Lucien" uniqKey="Israel L" first="Lucien" last="Israel">Lucien Israel</name><affiliation><mods:affiliation>Hôpital Avicenne, Bobigny, France</mods:affiliation></affiliation></author><author><name sortKey="Fargeot, Pierre" sort="Fargeot, Pierre" uniqKey="Fargeot P" first="Pierre" last="Fargeot">Pierre Fargeot</name><affiliation><mods:affiliation>Centre Georges François Leclerc, Dijon, France</mods:affiliation></affiliation></author><author><name sortKey="Lambert, Daniel" sort="Lambert, Daniel" uniqKey="Lambert D" first="Daniel" last="Lambert">Daniel Lambert</name><affiliation><mods:affiliation>C.H.R.U.—Hôpital du bocage, Dijon, France</mods:affiliation></affiliation></author><author><name sortKey="Delaunay, Michelle" sort="Delaunay, Michelle" uniqKey="Delaunay M" first="Michelle" last="Delaunay">Michelle Delaunay</name><affiliation><mods:affiliation>Hôpital Pellegrin Tripode, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dreno">Brigitte Dreno</name><affiliation><mods:affiliation>C.H.U. Hotel-Dieu, Nantes, France</mods:affiliation></affiliation></author><author><name sortKey="Vilmer, Catherine" sort="Vilmer, Catherine" uniqKey="Vilmer C" first="Catherine" last="Vilmer">Catherine Vilmer</name><affiliation><mods:affiliation>Centre René Huguenin, Saint-Cloud, France</mods:affiliation></affiliation></author><author><name sortKey="Bizzari, Jean P" sort="Bizzari, Jean P" uniqKey="Bizzari J" first="Jean-P" last="Bizzari">Jean-P Bizzari</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author><author><name sortKey="Cour, Veronique" sort="Cour, Veronique" uniqKey="Cour V" first="Véronique" last="Cour">Véronique Cour</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0959-8049(92)90008-P</idno><idno type="url">https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000845</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000845</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Fotemustine plus dacarbazine for malignant melanoma</title><author><name sortKey="Avril, Marie F" sort="Avril, Marie F" uniqKey="Avril M" first="Marie-F" last="Avril">Marie-F Avril</name><affiliation><mods:affiliation>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Bonneterre, Jean" sort="Bonneterre, Jean" uniqKey="Bonneterre J" first="Jean" last="Bonneterre">Jean Bonneterre</name><affiliation><mods:affiliation>Centre Oscar Lambret, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Cupissol, Didier" sort="Cupissol, Didier" uniqKey="Cupissol D" first="Didier" last="Cupissol">Didier Cupissol</name><affiliation><mods:affiliation>Centre Val d'Aurelle, Montpellier, France</mods:affiliation></affiliation></author><author><name sortKey="Grob, Jean J" sort="Grob, Jean J" uniqKey="Grob J" first="Jean-J" last="Grob">Jean-J Grob</name><affiliation><mods:affiliation>Hôpital Sainte-Marguerite, Marseille, France</mods:affiliation></affiliation></author><author><name sortKey="Kalis, Bernard" sort="Kalis, Bernard" uniqKey="Kalis B" first="Bernard" last="Kalis">Bernard Kalis</name><affiliation><mods:affiliation>Hôpital Sébastopol, Reims, France</mods:affiliation></affiliation></author><author><name sortKey="Fumoleau, Pierre" sort="Fumoleau, Pierre" uniqKey="Fumoleau P" first="Pierre" last="Fumoleau">Pierre Fumoleau</name><affiliation><mods:affiliation>Centre René Gauducheau, Nantes, France</mods:affiliation></affiliation></author><author><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name><affiliation><mods:affiliation>Centre Eugène Marquis, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Israel, Lucien" sort="Israel, Lucien" uniqKey="Israel L" first="Lucien" last="Israel">Lucien Israel</name><affiliation><mods:affiliation>Hôpital Avicenne, Bobigny, France</mods:affiliation></affiliation></author><author><name sortKey="Fargeot, Pierre" sort="Fargeot, Pierre" uniqKey="Fargeot P" first="Pierre" last="Fargeot">Pierre Fargeot</name><affiliation><mods:affiliation>Centre Georges François Leclerc, Dijon, France</mods:affiliation></affiliation></author><author><name sortKey="Lambert, Daniel" sort="Lambert, Daniel" uniqKey="Lambert D" first="Daniel" last="Lambert">Daniel Lambert</name><affiliation><mods:affiliation>C.H.R.U.—Hôpital du bocage, Dijon, France</mods:affiliation></affiliation></author><author><name sortKey="Delaunay, Michelle" sort="Delaunay, Michelle" uniqKey="Delaunay M" first="Michelle" last="Delaunay">Michelle Delaunay</name><affiliation><mods:affiliation>Hôpital Pellegrin Tripode, Bordeaux, France</mods:affiliation></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dreno">Brigitte Dreno</name><affiliation><mods:affiliation>C.H.U. Hotel-Dieu, Nantes, France</mods:affiliation></affiliation></author><author><name sortKey="Vilmer, Catherine" sort="Vilmer, Catherine" uniqKey="Vilmer C" first="Catherine" last="Vilmer">Catherine Vilmer</name><affiliation><mods:affiliation>Centre René Huguenin, Saint-Cloud, France</mods:affiliation></affiliation></author><author><name sortKey="Bizzari, Jean P" sort="Bizzari, Jean P" uniqKey="Bizzari J" first="Jean-P" last="Bizzari">Jean-P Bizzari</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author><author><name sortKey="Cour, Veronique" sort="Cour, Veronique" uniqKey="Cour V" first="Véronique" last="Cour">Véronique Cour</name><affiliation><mods:affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="ISSN">0959-8049</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1807">1807</biblScope><biblScope unit="page" to="1811">1811</biblScope></imprint><idno type="ISSN">0959-8049</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Alkaline phosphatases</term><term>Biometric parameters</term><term>Cancer chemother</term><term>Centre</term><term>Cerebral lesions</term><term>Cerebral metastases</term><term>Chemotherapy</term><term>Clinical trials</term><term>Combination chemotherapy</term><term>Complete response</term><term>Complete responses</term><term>Dacarbazine</term><term>Disease progression</term><term>Dominant metastatic site</term><term>Early death</term><term>Eurj cancer</term><term>Evaluable</term><term>Evaluable patients</term><term>Final evaluation</term><term>Fotemustine</term><term>Grade leukopenia</term><term>Haematological</term><term>Haematological toxicity</term><term>High performance</term><term>Hopital</term><term>Induction cycle</term><term>Lesion</term><term>Limb perfusion</term><term>Maintenance cycle</term><term>Malignant</term><term>Malignant melanoma</term><term>Median</term><term>Median days</term><term>Median duration</term><term>Median durations</term><term>Median nadir</term><term>Median survival time</term><term>Melanoma</term><term>Melphalan</term><term>Metastasis</term><term>Metastatic</term><term>Metastatic melanoma</term><term>Monotherapy</term><term>Natural history</term><term>Objective responses</term><term>Overall response rate</term><term>Partial response</term><term>Partial responses</term><term>Present series</term><term>Prognostic factors</term><term>Regimen</term><term>Response range</term><term>Response rate</term><term>Response rates</term><term>Toxicity</term><term>Visceral lesions</term><term>Visceral metastases</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: 119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>melanoma</json:string><json:string>fotemustine</json:string><json:string>metastasis</json:string><json:string>dacarbazine</json:string><json:string>toxicity</json:string><json:string>malignant</json:string><json:string>metastatic</json:string><json:string>response rate</json:string><json:string>malignant melanoma</json:string><json:string>melphalan</json:string><json:string>chemotherapy</json:string><json:string>median</json:string><json:string>monotherapy</json:string><json:string>hopital</json:string><json:string>evaluable</json:string><json:string>haematological</json:string><json:string>evaluable patients</json:string><json:string>median duration</json:string><json:string>induction cycle</json:string><json:string>regimen</json:string><json:string>combination chemotherapy</json:string><json:string>haematological toxicity</json:string><json:string>cerebral metastases</json:string><json:string>median days</json:string><json:string>lesion</json:string><json:string>visceral metastases</json:string><json:string>metastatic melanoma</json:string><json:string>complete responses</json:string><json:string>visceral lesions</json:string><json:string>grade leukopenia</json:string><json:string>dominant metastatic site</json:string><json:string>centre</json:string><json:string>partial response</json:string><json:string>present series</json:string><json:string>early death</json:string><json:string>disease progression</json:string><json:string>maintenance cycle</json:string><json:string>cerebral lesions</json:string><json:string>alkaline phosphatases</json:string><json:string>objective responses</json:string><json:string>median survival time</json:string><json:string>overall response rate</json:string><json:string>median nadir</json:string><json:string>complete response</json:string><json:string>biometric parameters</json:string><json:string>final evaluation</json:string><json:string>partial responses</json:string><json:string>prognostic factors</json:string><json:string>median durations</json:string><json:string>response range</json:string><json:string>natural history</json:string><json:string>clinical trials</json:string><json:string>cancer chemother</json:string><json:string>eurj cancer</json:string><json:string>response rates</json:string><json:string>limb perfusion</json:string><json:string>high performance</json:string></teeft></keywords><author><json:item><name>Marie-F Avril</name><affiliations><json:string>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France</json:string></affiliations></json:item><json:item><name>Jean Bonneterre</name><affiliations><json:string>Centre Oscar Lambret, Lille, France</json:string></affiliations></json:item><json:item><name>Didier Cupissol</name><affiliations><json:string>Centre Val d'Aurelle, Montpellier, France</json:string></affiliations></json:item><json:item><name>Jean-J Grob</name><affiliations><json:string>Hôpital Sainte-Marguerite, Marseille, France</json:string></affiliations></json:item><json:item><name>Bernard Kalis</name><affiliations><json:string>Hôpital Sébastopol, Reims, France</json:string></affiliations></json:item><json:item><name>Pierre Fumoleau</name><affiliations><json:string>Centre René Gauducheau, Nantes, France</json:string></affiliations></json:item><json:item><name>Pierre Kerbrat</name><affiliations><json:string>Centre Eugène Marquis, Rennes, France</json:string></affiliations></json:item><json:item><name>Lucien Israel</name><affiliations><json:string>Hôpital Avicenne, Bobigny, France</json:string></affiliations></json:item><json:item><name>Pierre Fargeot</name><affiliations><json:string>Centre Georges François Leclerc, Dijon, France</json:string></affiliations></json:item><json:item><name>Daniel Lambert</name><affiliations><json:string>C.H.R.U.—Hôpital du bocage, Dijon, France</json:string></affiliations></json:item><json:item><name>Michelle Delaunay</name><affiliations><json:string>Hôpital Pellegrin Tripode, Bordeaux, France</json:string></affiliations></json:item><json:item><name>Brigitte Dreno</name><affiliations><json:string>C.H.U. Hotel-Dieu, Nantes, France</json:string></affiliations></json:item><json:item><name>Catherine Vilmer</name><affiliations><json:string>Centre René Huguenin, Saint-Cloud, France</json:string></affiliations></json:item><json:item><name>Jean-P Bizzari</name><affiliations><json:string>Institut de Recherches Internationales Servier, Courbevoie, France</json:string></affiliations></json:item><json:item><name>Véronique Cour</name><affiliations><json:string>Institut de Recherches Internationales Servier, Courbevoie, France</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-NN62TZTW-Z</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: 119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.</abstract><qualityIndicators><score>7.295</score><pdfWordCount>3243</pdfWordCount><pdfCharCount>21305</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>591 x 806 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>171</abstractWordCount><abstractCharCount>1100</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Fotemustine plus dacarbazine for malignant melanoma</title><pmid><json:string>1389514</json:string></pmid><pii><json:string>0959-8049(92)90008-P</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Proc Am Soc Clin Oncol</title><language><json:string>unknown</json:string></language><volume>9</volume><pages><first>276</first></pages></serie><host><title>European Journal of Cancer</title><language><json:string>unknown</json:string></language><publicationDate>1992</publicationDate><issn><json:string>0959-8049</json:string></issn><pii><json:string>S0959-8049(00)X0170-0</json:string></pii><volume>28</volume><issue>11</issue><pages><first>1807</first><last>1811</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1992</json:string><json:string>between May 1988 and October 1989</json:string></date><geogName></geogName><orgName><json:string>Department of Dermatology, University of Glasgow, Glasgow</json:string><json:string>Lucien Israel, Pierre Fargeot, Daniel Lambert, Michelle Delaunay, Brigitte Dreno, Catherine Vilmer, Jean</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Henri Becquerel</json:string><json:string>R.N. Scott</json:string><json:string>Didier Cupissol</json:string><json:string>D. J. Kerr</json:string><json:string>Antoine Lacassagne</json:string><json:string>Bruno Audhuy</json:string><json:string>C.H.U. HotelDieu</json:string><json:string>J. Grob</json:string><json:string>Georges Francois</json:string><json:string>Camille Desmoulins</json:string><json:string>J. Hughes</json:string><json:string>Alexis Vautrin</json:string><json:string>U.K. Revised</json:string><json:string>A.J. McKay</json:string><json:string>G. Burnside</json:string><json:string>Oscar Lambret</json:string><json:string>R. Blackie</json:string><json:string>Eugene Marquis</json:string><json:string>L. Verret</json:string><json:string>Veronique Devignes</json:string><json:string>M.F. Avril</json:string><json:string>Louis Pasteur</json:string><json:string>Moise Namer</json:string><json:string>A. J. McKay</json:string><json:string>Pierre Kerbrat</json:string><json:string>Jean Bonneterre</json:string><json:string>Alain Bernadou</json:string><json:string>D.S. Byrne</json:string><json:string>Bernard Kalis</json:string><json:string>Edouard Grosshans</json:string><json:string>P. Cesarini</json:string><json:string>R.M. MacKie</json:string><json:string>P. Bizzari</json:string><json:string>Mireille Mousseau</json:string><json:string>Pierre Fumoleau</json:string><json:string>Final</json:string><json:string>M. Metastases</json:string><json:string>Gustave Roussy</json:string></persName><placeName><json:string>Montpellier</json:string><json:string>Grenoble</json:string><json:string>Toxicity</json:string><json:string>Rennes</json:string><json:string>Nice</json:string><json:string>Reims</json:string><json:string>Nantes</json:string><json:string>Strasbourg</json:string><json:string>Dijon</json:string><json:string>Colmar</json:string><json:string>Glasgow</json:string><json:string>Metz</json:string><json:string>Speyer</json:string><json:string>France</json:string><json:string>Marseille</json:string><json:string>Courbevoie</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>May 1988</json:string><json:string>Department of Vascular Surgery, Gartnavel General Hospital, 1053</json:string><json:string>F. Avril et al. 1808</json:string><json:string>[3]</json:string><json:string>[9]</json:string><json:string>F. Avril et al.</json:string><json:string>[2]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-NN62TZTW-Z</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - oncology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - oncology & carcinogenesis</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Cancer Research</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate><doi><json:string>10.1016/0959-8049(92)90008-P</json:string></doi><id>5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Fotemustine plus dacarbazine for malignant melanoma</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1992</date></publicationStmt><notesStmt><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Fotemustine plus dacarbazine for malignant melanoma</title><author xml:id="author-0000"><persName><forename type="first">Marie-F</forename><surname>Avril</surname></persName><note type="correspondence"><p>Correspondence to M.F. Avril.</p></note><affiliation>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Jean</forename><surname>Bonneterre</surname></persName><affiliation>Centre Oscar Lambret, Lille, France</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Didier</forename><surname>Cupissol</surname></persName><affiliation>Centre Val d'Aurelle, Montpellier, France</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Jean-J</forename><surname>Grob</surname></persName><affiliation>Hôpital Sainte-Marguerite, Marseille, France</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Bernard</forename><surname>Kalis</surname></persName><affiliation>Hôpital Sébastopol, Reims, France</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Pierre</forename><surname>Fumoleau</surname></persName><affiliation>Centre René Gauducheau, Nantes, France</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Pierre</forename><surname>Kerbrat</surname></persName><affiliation>Centre Eugène Marquis, Rennes, France</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Lucien</forename><surname>Israel</surname></persName><affiliation>Hôpital Avicenne, Bobigny, France</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Pierre</forename><surname>Fargeot</surname></persName><affiliation>Centre Georges François Leclerc, Dijon, France</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Daniel</forename><surname>Lambert</surname></persName><affiliation>C.H.R.U.—Hôpital du bocage, Dijon, France</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Michelle</forename><surname>Delaunay</surname></persName><affiliation>Hôpital Pellegrin Tripode, Bordeaux, France</affiliation></author><author xml:id="author-0011"><persName><forename type="first">Brigitte</forename><surname>Dreno</surname></persName><affiliation>C.H.U. Hotel-Dieu, Nantes, France</affiliation></author><author xml:id="author-0012"><persName><forename type="first">Catherine</forename><surname>Vilmer</surname></persName><affiliation>Centre René Huguenin, Saint-Cloud, France</affiliation></author><author xml:id="author-0013"><persName><forename type="first">Jean-P</forename><surname>Bizzari</surname></persName><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation></author><author xml:id="author-0014"><persName><forename type="first">Véronique</forename><surname>Cour</surname></persName><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation></author><idno type="istex">5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24</idno><idno type="DOI">10.1016/0959-8049(92)90008-P</idno><idno type="PII">0959-8049(92)90008-P</idno></analytic><monogr><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="pISSN">0959-8049</idno><idno type="PII">S0959-8049(00)X0170-0</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1807">1807</biblScope><biblScope unit="page" to="1811">1811</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.</p></abstract></profileDesc><revisionDesc><change when="1992">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>EJC</jid><aid>9290008P</aid><ce:pii>0959-8049(92)90008-P</ce:pii><ce:doi>10.1016/0959-8049(92)90008-P</ce:doi><ce:copyright type="unknown" year="1992"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Fotemustine plus dacarbazine for malignant melanoma</ce:title><ce:author-group><ce:author><ce:given-name>Marie-F</ce:given-name><ce:surname>Avril</ce:surname><ce:cross-ref refid="COR1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jean</ce:given-name><ce:surname>Bonneterre</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Didier</ce:given-name><ce:surname>Cupissol</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jean-J</ce:given-name><ce:surname>Grob</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Bernard</ce:given-name><ce:surname>Kalis</ce:surname><ce:cross-ref refid="AFF5"><ce:sup>5</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Pierre</ce:given-name><ce:surname>Fumoleau</ce:surname><ce:cross-ref refid="AFF6"><ce:sup>6</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Pierre</ce:given-name><ce:surname>Kerbrat</ce:surname><ce:cross-ref refid="AFF7"><ce:sup>7</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Lucien</ce:given-name><ce:surname>Israel</ce:surname><ce:cross-ref refid="AFF8"><ce:sup>8</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Pierre</ce:given-name><ce:surname>Fargeot</ce:surname><ce:cross-ref refid="AFF9"><ce:sup>9</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Daniel</ce:given-name><ce:surname>Lambert</ce:surname><ce:cross-ref refid="AFF10"><ce:sup>10</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Michelle</ce:given-name><ce:surname>Delaunay</ce:surname><ce:cross-ref refid="AFF11"><ce:sup>11</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Brigitte</ce:given-name><ce:surname>Dreno</ce:surname><ce:cross-ref refid="AFF12"><ce:sup>12</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Catherine</ce:given-name><ce:surname>Vilmer</ce:surname><ce:cross-ref refid="AFF13"><ce:sup>13</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jean-P</ce:given-name><ce:surname>Bizzari</ce:surname><ce:cross-ref refid="AFF14"><ce:sup>14</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Véronique</ce:given-name><ce:surname>Cour</ce:surname><ce:cross-ref refid="AFF14"><ce:sup>14</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>1</ce:label><ce:textfn>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>2</ce:label><ce:textfn>Centre Oscar Lambret, Lille, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>3</ce:label><ce:textfn>Centre Val d'Aurelle, Montpellier, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>4</ce:label><ce:textfn>Hôpital Sainte-Marguerite, Marseille, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF5"><ce:label>5</ce:label><ce:textfn>Hôpital Sébastopol, Reims, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF6"><ce:label>6</ce:label><ce:textfn>Centre René Gauducheau, Nantes, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF7"><ce:label>7</ce:label><ce:textfn>Centre Eugène Marquis, Rennes, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF8"><ce:label>8</ce:label><ce:textfn>Hôpital Avicenne, Bobigny, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF9"><ce:label>9</ce:label><ce:textfn>Centre Georges François Leclerc, Dijon, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF10"><ce:label>10</ce:label><ce:textfn>C.H.R.U.—Hôpital du bocage, Dijon, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF11"><ce:label>11</ce:label><ce:textfn>Hôpital Pellegrin Tripode, Bordeaux, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF12"><ce:label>12</ce:label><ce:textfn>C.H.U. Hotel-Dieu, Nantes, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF13"><ce:label>13</ce:label><ce:textfn>Centre René Huguenin, Saint-Cloud, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF14"><ce:label>14</ce:label><ce:textfn>Institut de Recherches Internationales Servier, Courbevoie, France</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>1</ce:label><ce:text>Correspondence to M.F. Avril.</ce:text></ce:correspondence></ce:author-group><ce:date-accepted day="27" month="1" year="1992"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>119 patients with metastatic melanoma received fotemustine 100 mg/m<ce:sup>2</ce:sup> on days 1 and 8 and dacarbazine 250 mg/m<ce:sup>2</ce:sup> on days 15–18. After a 5-week rest, fotemustine 100 mg/m<ce:sup>2</ce:sup> on day 1 and dacarbazine 250 mg/m<ce:sup>2</ce:sup> on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Fotemustine plus dacarbazine for malignant melanoma</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Fotemustine plus dacarbazine for malignant melanoma</title></titleInfo><name type="personal"><namePart type="given">Marie-F</namePart><namePart type="family">Avril</namePart><affiliation>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France</affiliation><description>Correspondence to M.F. Avril.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean</namePart><namePart type="family">Bonneterre</namePart><affiliation>Centre Oscar Lambret, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Didier</namePart><namePart type="family">Cupissol</namePart><affiliation>Centre Val d'Aurelle, Montpellier, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean-J</namePart><namePart type="family">Grob</namePart><affiliation>Hôpital Sainte-Marguerite, Marseille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Kalis</namePart><affiliation>Hôpital Sébastopol, Reims, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Fumoleau</namePart><affiliation>Centre René Gauducheau, Nantes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Kerbrat</namePart><affiliation>Centre Eugène Marquis, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lucien</namePart><namePart type="family">Israel</namePart><affiliation>Hôpital Avicenne, Bobigny, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Fargeot</namePart><affiliation>Centre Georges François Leclerc, Dijon, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Lambert</namePart><affiliation>C.H.R.U.—Hôpital du bocage, Dijon, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michelle</namePart><namePart type="family">Delaunay</namePart><affiliation>Hôpital Pellegrin Tripode, Bordeaux, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Brigitte</namePart><namePart type="family">Dreno</namePart><affiliation>C.H.U. Hotel-Dieu, Nantes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Catherine</namePart><namePart type="family">Vilmer</namePart><affiliation>Centre René Huguenin, Saint-Cloud, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean-P</namePart><namePart type="family">Bizzari</namePart><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Véronique</namePart><namePart type="family">Cour</namePart><affiliation>Institut de Recherches Internationales Servier, Courbevoie, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: 119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.</abstract><note type="content">Section title: Paper</note><relatedItem type="host"><titleInfo><title>European Journal of Cancer</title></titleInfo><titleInfo type="abbreviated"><title>EJC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued></originInfo><identifier type="ISSN">0959-8049</identifier><identifier type="PII">S0959-8049(00)X0170-0</identifier><part><date>1992</date><detail type="volume"><number>28</number><caption>vol.</caption></detail><detail type="issue"><number>11</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1777</start><end>1935</end></extent><extent unit="pages"><start>1807</start><end>1811</end></extent></part></relatedItem><identifier type="istex">5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24</identifier><identifier type="ark">ark:/67375/6H6-NN62TZTW-Z</identifier><identifier type="DOI">10.1016/0959-8049(92)90008-P</identifier><identifier type="PII">0959-8049(92)90008-P</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/metadata/json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000845 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000845 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24
|texte= Fotemustine plus dacarbazine for malignant melanoma
}}
| This area was generated with Dilib version V0.6.33. |  |